Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia cancer agency experience

Cancer Investigation

Volumn 25, Issue 8, 2007, Pages 711-714

  Wilson, Kenneth S ^a,b,d   Fitzgerald, Catherine A ^a,b,d   Barnett, Jeff B ^b   Gill, Sharlene ^a,c,d   Khoo, Kong E ^a,b,d  

^a Vancouver Island Centre   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c Vancouver Centre   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

5FU intolerance; Adjuvant; Colorectal cancer; Raltitrexed

Indexed keywords

FLUOROURACIL; RALTITREXED;

ADJUVANT THERAPY; ADULT; AGED; ARTHRALGIA; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HEMATOLOGIC DISEASE; HUMAN; MUCOSAL DISEASE; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; QUINAZOLINES; RETROSPECTIVE STUDIES; THIOPHENES;

EID: 36849050218     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701518388     Document Type: Article

References (28)

1. Jemal, A.; Siegel, R.; Ward, E.; et al. Cancer Statistics, 2006. CA. Cancer. J. Clin. 2006, 56, 106-130.
2. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995, 345, 939-944.
3. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. J. Am. Med. Assoc. 1990, 264, 444-450.
4. Omura K. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5FU-based chemotherapy: Mutatations in the DPD gene and DPD inhibitory fluoropyrimidines. Int. J. Clin. Oncol. 2003, 8, 132-138.
5. Cunningham D. Mature results from three large controlled studies with raltitrexed ('Tomudex'). Br. J. Cancer 1998, 77(2), 15-21.
6. Cunningham D, Zalcberg JR, Rath U et al. 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group. Eur. J. Cancer 1995, 31A(12), 1945-1954.
7. Drug company decision to end cancer trial. Lancet 1999, 354, 1045.
8. Judson I, Maughan T, Beale P et al. Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694). Br. J. Cancer 1998, 78(9), 1188-1193.
9. 20(7-8), 992-995.
10. British Columbia Cancer Agency GI Tumour Group. BCCA Protocol Summary for palliative chemotherapy for metastatic colorectal cancer using raltitrexed in patients with previous fluoro-uracil toxicity. Available at: http://www.bccancer.bc.ca/NR/rdonlyres/C0A8933B-3AAD-4EBA-A95C-4552A0A060C9/ 14355/GIRALT1mar2006.pdf Accessed March 2006.
11. Kempin S, Gutierrez J, Wilson E et al. Raltitrexed (Tomudex): an alternative choice in patients intolerant to 5-fluorouracil. Cancer Investigation 2002, 20(7-8), 992-995.
12. British Columbia Cancer Agency GI Tumour Group. BCCA Protocol Summary for stage III and high risk stage II colon cancer using leucovorin and fluorouracil. Available at: http://www.bccancer.bc.ca/NR/rdonlyres/C0A8933B- 3AAD-4EBA-A95C-4552A0A060C9/14335/GIFFAD1mar2006.pdf Accessed 20 March 2006.
13. British Columbia Cancer Agency GI Tumour Group. BCCA Protocol Summary for rectal carcinoma using fluorouracil + leucovorin + XRT. Available at: http://www.bccancer.bc.ca/NR/rdonlyres/C0A8933B-3AAD-4EBA-A95C-4552A0A060C9/ 14354/GIRAI1mar2006.pdf. Accessed 20 March 2006.
14. Colon and rectum. In: American Joint Committee on Cancer: AJCC Cancer Staging Manual. 6th edition, New York, NY: Springer, 2002, 113-124.
15. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958, 53, 457-481.
16. Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Part II: Analysis and Examples. Brit. J. Cancer 1977, 35, 1-39.
17. Marsoni S. Efficacy of adjuvant fluorouracil and leucovorin in stage B2 and C colon cancer. International Multicenter Pooled Analysis of Colon Cancer Trials Investigators. Semin. Oncol. 2001, 28(Suppl 1), 14-19.
18. Twelves C, Wong A, Nowacki M P et al. Capecitabine as Adjuvant Treatment for Stage III Colon Cancer. N. Engl. J. Med. 2005, 352, 2696-2704.
19. Tomiak A, Vincent M, Kocha W et al. Standard dose (Mayo regimen) 5-fluorouracil and low dose folinic acid: prohibitive toxicity? Am. J. Clin. Oncol. 2000, 23, 94-98.
20. Weinerman B. Increased incidence of toxicity in elderly females treated with 5FU, leucovorin. Proc. Am. Soc. Clin. Oncol. 1996: abstract 541.
21. Sloan JA, Goldberg RM, Sargent, DJ, et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J. Clin. Oncol. 2002, 20, 1491-1498.
22. Zalcberg J, Cunningham D, Rath U et al. Modulated 5FU: female gender and increasing age are associated with significantly more grade 3 or 4 leucopenia or mucositis. Proc. Am. Soc. Clin. Oncol. 1996, abstract 447.
23. Zalcberg J. Overview of the tolerability of Tomudex (raltitrexed): collective clinical experience in advanced colorectal cancer. Anti-Cancer Drugs 1997, 8(Suppl 2), S17-S22.
24. Schuell B, Gruenberger T, Kornek GV et al. Side effects during chemotherapy predict tumour response in advanced colorectal cancer. Brit. J. Cancer 2005, 93, 744-748.
25. Shah A, Macdonald W, Goldie J. 5FU infusion in advanced colorectal cancer: a comparison of 3 dose schedules. Cancer Treatment Reports 1985, 69, 739-742.
26. Browman G, Shah A, Ayoub J et al. Surrogate endpoints in colorectal cancer. Current Oncology 2005, 12(4), 136-146.
27. Sargent DJ, Wieand HS, Haller DG et al. Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials. J. Clin. Oncol. 2005, 23, 8664-8670.
28. British Columbia Cancer Agency GI Tumour Group. BCCA Protocol Summary for Adjuvant Therapy of Colon Cancer using Capecitabine. Availble at: http://www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Gastrointestinal/GIAJCAP. htm. Accessed March 2006.